Cirurgia:

Oncologia Clínica:

Referências:

Oncologia clínica

GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 - Presenting Author: Sara A. Hurvitz, MD, FACP – University of California Los Angeles

Abstract GS2-01 - Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02 - Presenting Author: Ian Krop, MD, PhD – Dana-Farber Cancer Institute

Abstract GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer - Presenting Author: Aditya Bardia, MD, MPH – Mass General Cancer Center, Harvard Medical School

GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting  - Presenting Author: Aditya Bardia, MD, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA;

Abstract GS3-02 - Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial - Presenting Author: Mafalda Oliveira, MD, PhD – Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology

Abstract GS3-04 - Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial - Presenting Author: Nicholas Turner, MD, PhD – The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Cirurgia

PD15-08 Brazilian Randomized Study - BREAST-MRI Trial - Impact of Preoperative Magnetic Resonance in the Evaluation for Breast Cancer Conservative Surgery: Local recurrence and surgical outcomes - Presenting Author: Bruna S. Mota, MD, PhD, Physician Assistant - Instituto do Cancer do Estado de São Paulo;

PD15-11 Axillary dissection to determine nodal burden to inform systemic therapy recommendations in patients with clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) - Presenting Author: Walter P. Weber, MD, Chief Physician - Breast Center, University Hospital of Basel, Basel, Switzerland

PD15-04 Overall survival following breast conserving surgery and adjuvant radiotherapy compared with mastectomy for early stage breast cancer: a systematic review and metaanalysis - Presenting Author: Kiran Kasper Rajan, MBBS MSc, Academic Foundation Doctor - Bristol Medical School

PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS) - Presenting Author: Oukseub Lee, Ph.D., Research assistant professor - Northwestern University

Abstract GS4-01 - Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from ACOSOG Z11102 (Alliance) - Presenting Author: Judy C. Boughey, MD – Mayo Clinic

GS4-02 Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study - Presenting Author: Giacomo Montagna, MD, MPH, Breast Surgeon - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA